Epigenomics : from chromatin biology to therapeutics /
Experts from academia, the biotechnology and pharmaceutical industries introduce biological, medical and methodological aspects of the emerging field of epigenomics.
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cambridge :
Cambridge University Press,
2012.
|
| Subjects: | |
| Online Access: | CONNECT |
Table of Contents:
- Cover; Epigenomics From Chromatin Biology to Therapeutics; Title; Copyright; Dedication; Contents; Contributors; Foreword; Preface; Part I Basics of chromatin biology and biochemistry; 1 Introduction to epigenomics; X-chromosome inactivation (dosage compensation); Genetic imprinting; Epigetic modifications and their mechanisms; Scope of this book; Part I: Basics of chromatin biology and biochemistry; Part II: Epigenomic imprinting and stem cells; Part III: Epigenomic assays and sequencing technology; Part IV: Epigenomics in disease biology; Part V: Epigenomics in neurodegenerative diseases.
- Part VI: Epigenetic variation, polymorphism, and epidemiological perspectivesCurrent issues in epigenomics; Identical twins; Future developments in epigenomics; References; 2 Epigenetics and its historical perspectives; 21 Introduction; 22 Inheritance in somatic cells; 23 Epimutations and dual inheritance; 24 Cancer and de novo methylation; 25 Chromatin remodeling; 26 Differences between genetic and epigenetic systems; 27 An epigenetic component in long-term memory?; 28 A wider definition of epigenetics; 29 The chronology of epigenetics; References.
- 3 Functional networks of human epigenetic factors31 Introduction; 32 Methodology; 321 Design of reporter cell systems; 322 SiRNA-based knockdown analysis; 323 High-throughput siRNA screening; 324 Considerations for design and analysis of the siRNA screen; 33 Results and discussion; 331 Proof-of-concept study to identify factors and networks that participate in epigenetic gene silencing; 332 Design of siRNA library; 333 SiRNA high-throughput screening; 334 Identities of screen hits; 335 Evaluating position-specific versus epigenome-wide roles for silencing factors.
- 336 Evidence for crosstalk between DNA methylation and histone modifications337 Interpreting output from epigenetic factor screens; 338 Identifying networks of "targetable" epigenetic factors; 34 Summary; Acknowledgements; References; 4 Nucleosome positioning in promoters: significance and open questions; 41 Introduction; 411 Micrococcal nuclease bias; 412 To sequence or not to sequence?; 42 Factors potentially affecting nucleosome positioning; 421 Pitfalls of sequence analysis; 422 Periodicity or artifact?; 423 DNA bendability and nucleosome positioning.
- 424 Nucleosome positioning, histone modifications, and DNA methylation43 Hypotheses; 431 Transcription-coupled nucleosome positioning; 432 Chromatin structure as a cancer lineage classifier; 433 Retrotransposons and nucleosome positioning signals; 44 Concluding remarks; References; 5 Chemical reporters of protein methylation and acetylation; 51 Introduction; 52 Methodology; 521 Synthesis of chemical reporters; 522 In vitro transfer assays; 523 Labeling of cell lysates or living cells; 524 Determining the specificity of acetylation and methylation reporters.
